Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Ranitidine and sucralfate are widely used to prevent gastrointestinal
bleeding in patients in intensive care. Several recommendations suggest
this prophylaxis, but the Food and Drugs Administration (FDA) and the
European Medicines Evaluation Agency (EMEA) have not given their
approval. The meta-analysis by Messori et al (p 1103) shows that
ranitidine does not prevent gastrointestinal bleeding, and data for
sucralfate are insufficient to conclude anything on its effectiveness.
Ranitidine was found to increase the risk of pneumonia under certain
circumstances. Further trials are needed, but their design poses the
problem of whether placebo can be given to control groups.